Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in Migraine Prophylaxis
NCT00231595Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in migraine (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in monthly (28 day) migraine period rate at 26 weeks. Started Mar 2001; status: completed.
02
Drugs
topiramate
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00231595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231595.